Thr92Ala Polymorphism of Human Type 2 Deiodinase Gene (hD2) Affects the Development of Graves' Disease, Treatment Efficiency, and Rate of Remission
Clinical symptoms vary in thyrotoxicosis, and severity of these depends on many factors. Over the last years, impact of genetic factors upon the development and clinical significance of thyrotoxic symptoms became evident. It is known that a production of T3 in various tissues is limited by deiodinas...
Saved in:
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2012-01-01
|
Series: | Clinical and Developmental Immunology |
Online Access: | http://dx.doi.org/10.1155/2012/340542 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
_version_ | 1832548720445489152 |
---|---|
author | Babenko Alina Popkova Daria Freylihman Olga Solncev Vladislav Kostareva Anna Grineva Elena |
author_facet | Babenko Alina Popkova Daria Freylihman Olga Solncev Vladislav Kostareva Anna Grineva Elena |
author_sort | Babenko Alina |
collection | DOAJ |
description | Clinical symptoms vary in thyrotoxicosis, and severity of these depends on many factors. Over the last years, impact of genetic factors upon the development and clinical significance of thyrotoxic symptoms became evident. It is known that a production of T3 in various tissues is limited by deiodinase 2 (D2). Recent studies revealed that certain single nucleotide polymorphisms (including threonine (Thr) to alanine (Ala) replacement in D2 gene codon 92, D2 Thr92Ala) affect T3 levels in tissues and in serum. Individuals with Ala92Ala genotype have lower D2 activity in tissues, compared with that in individuals with other genotypes. In our study, we have assessed an association of D2 Thr92Ala polymorphism with (1) frequency of disease development, (2) severity of clinical symptoms of thyrotoxicosis, and (3) rate of remissions, in Graves' disease patients. |
format | Article |
id | doaj-art-fb8af667bdf142b18438ec99a9283008 |
institution | Kabale University |
issn | 1740-2522 1740-2530 |
language | English |
publishDate | 2012-01-01 |
publisher | Wiley |
record_format | Article |
series | Clinical and Developmental Immunology |
spelling | doaj-art-fb8af667bdf142b18438ec99a92830082025-02-03T06:13:25ZengWileyClinical and Developmental Immunology1740-25221740-25302012-01-01201210.1155/2012/340542340542Thr92Ala Polymorphism of Human Type 2 Deiodinase Gene (hD2) Affects the Development of Graves' Disease, Treatment Efficiency, and Rate of RemissionBabenko Alina0Popkova Daria1Freylihman Olga2Solncev Vladislav3Kostareva Anna4Grineva Elena5Institute of Endocrinology, Almazov Federal Heart, Blood and Endocrinology Centre, 2 Akkuratova Street, Saint-Petersburg 197541, RussiaInstitute of Endocrinology, Almazov Federal Heart, Blood and Endocrinology Centre, 2 Akkuratova Street, Saint-Petersburg 197541, RussiaInstitute of Molecular Biology and Genetics, Almazov Federal Heart, Blood and Endocrinology Centre, 2 Akkuratova Street, Saint-Petersburg 197541, RussiaDepartment of Mathematical Modeling, Almazov Federal Heart, Blood and Endocrinology Centre, 2 Akkuratova street, Saint-Petersburg 197541, RussiaInstitute of Molecular Biology and Genetics, Almazov Federal Heart, Blood and Endocrinology Centre, 2 Akkuratova Street, Saint-Petersburg 197541, RussiaInstitute of Endocrinology, Almazov Federal Heart, Blood and Endocrinology Centre, 2 Akkuratova Street, Saint-Petersburg 197541, RussiaClinical symptoms vary in thyrotoxicosis, and severity of these depends on many factors. Over the last years, impact of genetic factors upon the development and clinical significance of thyrotoxic symptoms became evident. It is known that a production of T3 in various tissues is limited by deiodinase 2 (D2). Recent studies revealed that certain single nucleotide polymorphisms (including threonine (Thr) to alanine (Ala) replacement in D2 gene codon 92, D2 Thr92Ala) affect T3 levels in tissues and in serum. Individuals with Ala92Ala genotype have lower D2 activity in tissues, compared with that in individuals with other genotypes. In our study, we have assessed an association of D2 Thr92Ala polymorphism with (1) frequency of disease development, (2) severity of clinical symptoms of thyrotoxicosis, and (3) rate of remissions, in Graves' disease patients.http://dx.doi.org/10.1155/2012/340542 |
spellingShingle | Babenko Alina Popkova Daria Freylihman Olga Solncev Vladislav Kostareva Anna Grineva Elena Thr92Ala Polymorphism of Human Type 2 Deiodinase Gene (hD2) Affects the Development of Graves' Disease, Treatment Efficiency, and Rate of Remission Clinical and Developmental Immunology |
title | Thr92Ala Polymorphism of Human Type 2 Deiodinase Gene (hD2) Affects the Development of Graves' Disease, Treatment Efficiency, and Rate of Remission |
title_full | Thr92Ala Polymorphism of Human Type 2 Deiodinase Gene (hD2) Affects the Development of Graves' Disease, Treatment Efficiency, and Rate of Remission |
title_fullStr | Thr92Ala Polymorphism of Human Type 2 Deiodinase Gene (hD2) Affects the Development of Graves' Disease, Treatment Efficiency, and Rate of Remission |
title_full_unstemmed | Thr92Ala Polymorphism of Human Type 2 Deiodinase Gene (hD2) Affects the Development of Graves' Disease, Treatment Efficiency, and Rate of Remission |
title_short | Thr92Ala Polymorphism of Human Type 2 Deiodinase Gene (hD2) Affects the Development of Graves' Disease, Treatment Efficiency, and Rate of Remission |
title_sort | thr92ala polymorphism of human type 2 deiodinase gene hd2 affects the development of graves disease treatment efficiency and rate of remission |
url | http://dx.doi.org/10.1155/2012/340542 |
work_keys_str_mv | AT babenkoalina thr92alapolymorphismofhumantype2deiodinasegenehd2affectsthedevelopmentofgravesdiseasetreatmentefficiencyandrateofremission AT popkovadaria thr92alapolymorphismofhumantype2deiodinasegenehd2affectsthedevelopmentofgravesdiseasetreatmentefficiencyandrateofremission AT freylihmanolga thr92alapolymorphismofhumantype2deiodinasegenehd2affectsthedevelopmentofgravesdiseasetreatmentefficiencyandrateofremission AT solncevvladislav thr92alapolymorphismofhumantype2deiodinasegenehd2affectsthedevelopmentofgravesdiseasetreatmentefficiencyandrateofremission AT kostarevaanna thr92alapolymorphismofhumantype2deiodinasegenehd2affectsthedevelopmentofgravesdiseasetreatmentefficiencyandrateofremission AT grinevaelena thr92alapolymorphismofhumantype2deiodinasegenehd2affectsthedevelopmentofgravesdiseasetreatmentefficiencyandrateofremission |